fbpx

molecules of the month

JNJ-54717793

oral, BP, selective OX1R GPCR antagonist

orally efficacious in panic attack models

from optimization of internal OX2R antagonist

ACS Med. Chem. Lett., May 5, 2020

Janssen R&D, San Diego, CA

JNJ-54717793
1 min read

JNJ-54717793 is a selective antagonist of the orexin-1 receptor intended for use in anxiety disorders, in contrast to dual orexin-1/2 inhibitors and orexin-2 inhibitors typically applied for sleep disorders. It’s a surprisingly large molecule (three aromatic rings and a bicycle) for an oral, brain-penetrant clinical candidate with predicted once-daily dosing in humans. This compound was very well-tolerated in preclinical species (NOAEL 250 mg/kg in rodent, 25 mg/kg in dog).


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: